Article

Accelerating clinical development with Generative AI

How artificial intelligence (AI) is revolutionizing drug development

As life sciences companies face the challenge of managing flexible, adaptable, and cost-effective trials, the integration of Generative AI (GenAI) may be a game-changer. Learn how GenAI in clinical trials can enhance operational efficiencies and help improve patient outcomes.

Unlocking new growth potential in clinical trials with GenAI

GenAI offers life sciences leaders a powerful tool to help streamline and enhance various stages of clinical trials. By automating key, repetitive tasks such as document generation and regulatory submissions, the technology can reduce overall cycle time and costs. Potential positive outcomes of GenAI in clinical trials include:

  • Improving study startup. Increase velocity by automating document generation activities. Working from previous examples of clinical trial protocols, site contracting agreements, and clinical report forms, biopharma organizations can quickly draft and refine the essential documentation required to establish new test sites. This can help foster diversity in patient cohorts and speed up site creation, reducing effort and costs.
  • Revolutionizing patient engagement and retention. Increase study retention by amplifying patient engagement. GenAI can personalize outreach, identify key doctors and locations, and answer patient questions, reducing early trial dropouts. This can cut costs significantly, as patient attrition can be as expensive as $20,000 per participant.1
  • Streamlining regulatory submissions. Improve regulatory engagement with tailored submissions. GenAI enables faster identification of relevant materials and automated document tagging, making it easier for clinical teams to assemble comprehensive dossiers for regulators.

Generative AI to accelerate clinical development

Gain in-depth insights into how GenAI can be used to enable faster, more efficient drug development processes.

Key considerations for GenAI in clinical trials

Many life sciences leaders are excited by the potential of applying GenAI to clinical trials. However, some are understandably concerned about managing risks to quality and employee experience. Consider the following when developing your strategy.

This section is an infogram

This message and the space it occupies will not be displayed when viewing this page either in Live, Preview, or "View as published" modes

Additional insights

Catalyze breakthroughs to advance the business of science

Insights and solutions that can help your business create a competitive advantage.

Explore the IndustryAdvantageTM platform

Integrating GenAI into your clinical trials

We understand that effectively integrating AI and GenAI across your life sciences enterprise can seem daunting. Our teams are here to help your business fuel innovation to lead in your industry.

If you’d like to learn more about how AI is revolutionizing drug development in the life sciences industry, let’s set up a conversation.

Get in touch

If you’d like to learn more about how Generative AI can drive supply chain transformation in the life sciences industry, let’s set up a conversation.

 

 

Andrew Bolt
Principal | Deloitte Consulting  LLP
anbolt@deloitte.com

Amy Cheung
Principal | Deloitte Consulting LLP
amyycheung@deloitte.com

Aditya Kudumala
Principal | Deloitte Consulting LLP
akudumala@deloitte.com

Adam Israel
Senior Manager | Deloitte  Consulting LLP
adisrael@deloitte.com

Fullwidth SCC. Do not delete! This box/component contains JavaScript that is needed on this page. This message will not be visible when page is activated.

Did you find this useful?